Putting people to the test. by Weinhold, B
Spheres of InfluenceHowever, concerns about human studies are sur-
facing in the wake of news reports of deaths among
human subjects. In 1999, an 18-year-old man died
during a University of Pennsylvania gene transfer
trial. In June 2001, a woman in a Johns Hopkins
asthma study died after inhaling a test substance.
And controversy erupted in March 2001 following
reports in The Seattle Times about high death rates in
a trial conducted from 1981 to 1993 at the Fred
Hutchinson Cancer Research Center.
Government agencies and researchers in the
United States and around the world have begun to
respond to these and other emerging problems with
a series of recommendations. For example, the U.S.
Environmental Protection Agency (EPA) asked its
Science Advisory Board in 1998 to review the use of
human test data, particularly in regards to making
pesticide registration decisions. But few recommen-
dations have been implemented. Meanwhile, the
parameters guiding the use of human subjects are “a
morass,” says Jeffrey Kahn, director of the Center for
Bioethics at the University of Minnesota in
Minneapolis and a member of the EPA Science
Advisory Board.
An Aging System Unravels
In the aftermath of the post–World War II
Nuremberg trials, which dealt in part with abuses
of people during biomedical experiments, a broad
set of standards for the use of human test subjects
has evolved. In the United States, the latest genera-
tion of standards, known as the Common Rule,
applies to 17 federal agencies, but not to organiza-
tions in the private sector that don’t receive federal
funding or that haven’t committed to following the
Common Rule.
These standards have helped protect people to
some degree as they have participated in experiments
designed to support public health standards for pollu-
tant exposures. However, the broad language of the
Common Rule has many grey areas, and questions
about those areas are being raised in the course of the
accelerating pace of health research and associated
financial and professional conflicts and pressures.
There also is a shortage of funding for oversight, and
an inability to pin down what the costs of oversight
even are. And organizations are generally unable to
develop ethical parameters as rapidly as they create
technological advances.
Despite the system’s flaws, Richard Sharp, a bio-
medical ethicist at the NIEHS, agrees with Koenig
that the use of human test subjects can be justified in
certain circumstances. In most cases, studies of
harmful substances are conducted on people already
exposed at work, home, or play, or in an accident.
However, those studies and complementary labo-
ratory and animal studies still leave knowledge gaps.
To help plug those gaps, government and private
researchers conduct an unknown number of studies
involving deliberate exposures.
Most deliberate exposure studies sponsored by
the EPA involve common air pollutants such as
ozone or particulates, says Peter Preuss, director of
the EPA’s National Center for Environmental
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The thought of deliberately exposing people to pollu-
tants sends a shudder down the spine of many people.
But when the complex reactions of humans to harmful substances can’t be evaluated
any other way, deliberate exposures can be justified for certain research, says Jane
Koenig, a professor of environmental health at the University of Washington School
of Public Health and Community Medicine. “There are no good animal models for
asthma,” she says. “We don’t even know what asthma is in humans. [And] you can’t
tell a rat to take a deep breath. You can’t ask them [about] symptoms, how they feel.”Research. In other studies sponsored by the
EPA and the NIH, people have been exposed
for short periods of time to low doses of sub-
stances such as toluene, xylene, chloroben-
zene, the gasoline additive MTBE, and the
parasite Cryptosporidium. Recent overseas
studies have exposed people to pesticides,
says Richard Wiles, senior vice president of
the Washington, D.C.–based advocacy orga-
nization Environmental Working Group
(EWG). Private companies, such as chemical
manufacturers, also conduct such research,
sometimes under no obligation to adhere to
government standards. 
“The current system for protecting
human subjects in large-scale multicenter
trials is outdated,” conclude Duke
University’s Michael Morse, Robert Califf,
and Jeremy Sugarman in a report published
in the 7 March 2001 issue of the Journal of
the American Medical Association. “It charges
IRBs [institutional review boards] with
functions that they cannot credibly per-
form.” The authors also criticize the adver-
sarial yet symbiotic relationships between
IRBs and data monitoring committees,
which sometimes are used to independently
assess a study and protect test subjects,
thereby putting them in the position of both
acting as watchdog and working to keep a
study on track. 
People at Risk
Under the current regulatory framework,
human test subjects are most vulnerable to
harm after a study begins, says Greg Koski,
director of the Office for Human Research
Protections, formed within the U.S.
Department of Health and Human
Services (HHS) in 2001, partly in response
to the death in the 1999 University of
Pennsylvania gene transfer trial. For
instance, participants often do not under-
stand that they can back out of a study (for
example, as they begin to feel side effects),
and little is done to make sure that a volun-
teer isn’t getting cold feet partway through
a study, he says.
Other problems occur even before a
study begins, when many volunteers likely
sign the typical consent form without
fully understanding the risks they will
face. “[The informed consent process] is
well-intended, but it falls short of the
mark,” Koski says. Some of the stumbling
blocks with informed consent are subtle.
“Like a lot of things, the devil is in the
details,” Sharp says. If the form cautions
that a person might suffer from “peripheral
neuropathy” as a result of a test, for
instance, that may not mean as much to a
layperson as the words “numbness in the
hands or feet.”
Janet Heinrich, director of health care
and public health issues at the U.S. General
Accounting Office, agrees. In May 2001 tes-
timony published prior to presentation
before the Subcommittee on Public Health
of the Senate Committee on Health,
Education, Labor, and Pensions, she said,
“While the guidance and information on
informed consent are extensive, [the
National Bioethics Advisory Commission]
has suggested that in general, the federal
guidance continues to emphasize document-
ing the subject’s consent rather than focus-
ing on the ethical practices for obtaining this
consent.” 
On a broader scale, organizations that
evaluate proposed studies involving deliber-
ate exposures, whether to pollutants, drugs,
medical devices, or treatment methods, usu-
ally try to identify the likely beneficiaries. If
a test involves a drug, medical device, or
treatment method for which an estimated
hundreds of thousands of people have been
test subjects, the risks of exposure may be
offset to some degree by potential benefits to
the individual or society.
However, if the primary beneficiary isn’t
an individual, or even society, but a compa-
ny that is trying to introduce or expand use
of a potentially toxic substance, then the
public or individual benefits are extremely
low or nonexistent, says Wiles.
A company-funded study came to light
in late 2000 when U.S. News & World
Report covered a Lockheed Martin Corp-
oration study of perchlorate, conducted in
response to a class-action lawsuit by resi-
dents of Mentone, California, who were
concerned about possible health problems
from the chemical. Perchlorate, which is
found in rocket fuel and some fertilizers, is
leaching from a former Lockheed Martin
plant near Mentone. 
Researchers at the Boston University
School of Medicine and Loma Linda
Medical Center in California, who were still
enrolling volunteers for test exposures in
mid-2001, note that perchlorate has been
used in thyroid treatments and that the level
of test exposure is “many-fold” less than his-
torical thyroid therapy doses. But the test
exposure level is still 83 times higher than
California standards for site cleanup, said
the U.S. News article. 
Lockheed Martin is helping to clean up
Mentone’s contaminated groundwater fol-
lowing a mandate from the state. Company
officials and researchers declined to release
additional information.
The study concerns
Wiles, especially if the results
are used to allow reduced
cleanup standards at the
Lockheed Martin site or else-
where. For example, if testing
shows no noticeable effects from doses
lower than existing standards, regulatory
officials might lean toward lowering stan-
dards. People such as Wiles are concerned
that limited tests from a focused human
study might not account for chronic effects
or synergistic actions when people are
exposed to other substances in the real
world. A similar chain of events has hap-
pened with pesticide studies, he notes,
with the findings used to relax exposure
standards. 
However, he does acknowledge that use
of human test subjects might be viable if a
study evaluated health effects from existing
ambient pollutants, such as sulfur dioxide
(primarily produced during fossil fuel com-
bustion), and if no other research methods
were available.
Sulfur dioxide is one of the substances
that Koenig has tested to evaluate its impact
on asthma. In a typical study, she recruits
10–40 volunteers, who are exposed one or
two times for 5–10 minutes each, she says,
with typical exposures in the range of
0.1–1.0 ppm. Many of her volunteers tend
to be older people who have time on their
hands or who find the study intellectually
stimulating. Others have asthma and are
curious to know about specific potential
irritants. Still others are students who want
to make a little money. But the pay is
skimpy, $20–30 for most tests, and is
designed primarily to compensate subjects
for the inconvenience of testing and to pay
for their parking. “IRBs don’t really like the
idea of us ‘buying’ subjects,” she says, par-
ticularly if the subjects are children made
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“The current system for protecting human subjects
in large-scale multicenter trials is outdated. 
It charges IRBs [institutional review boards] with functions
that they cannot credibly perform.” 
–Michael Morse, Robert Califf, and Jeremy Sugarman 
Duke Universityavailable by parents trying to make money. 
But some studies pay substantial sums.
In the Lockheed Martin study, some subjects
are being paid $1,000, according to U.S.
News & World Report. In another study, con-
ducted in San Francisco to evaluate the
effects of ozone on asthmatics, subjects are
being offered $1,000 for about 40 hours of
time. A recruiting company for the San
Francisco study, thehealthexchange.org
(one of several hundred such recruiting
companies), declined to disclose details of
the study, including who is conducting it.
But the company’s Web site did note that
exposures would occur in four-hour stretches
and would be at levels equivalent to those in
Los Angeles on a smoggy day. The same
company also was recruiting in mid-2001
for other studies: one that exposes people to
elevated temperatures to test effects on skin
circulation, another that exposes people
with asthma and chronic obstructive pul-
monary disease to air pollutants, and a third
that tests the effects of the pesticide perme-
thrin on dust mite allergy and concurrent
asthma symptoms. 
Pressures from researchers to recruit for
studies of all kinds are mounting, according
to the HHS Office of Inspector General
(OIG), primarily due to increasing demands
for more drugs and medical devices, but also
due in part to a push by government and
individuals for additional knowledge about
adverse health effects from the mix of pollu-
tants now present in the environment. The
OIG addressed many of the field’s problems
in a series of reports in 1998, then followed
those up with congressional testimony in
2000. OIG officials concluded in 2000 that,
along with many other problems with the
use of human test subjects, oversight of the
recruiting process is limited, and that con-
cerns regarding informed consent, patient
confidentiality, and eligibility for enrollment
remain.
Making Some Headway
Many researchers and regulatory agencies
around the world are focusing on solving
the numerous problems that persist with
the use of human test subjects. In the
United States, members of both the Senate
and the House of Representatives are craft-
ing legislative proposals, and more funding
will become available for fiscal year 2002.
The proposed budget for fiscal year 2002 is
expected to be nearly triple the $2.7 mil-
lion that was available just two years ago,
Koski says. The money is all within the
budget for the Office for Human Research
Protections, and would be used for over-
sight, education, compliance work, assis-
tance with development of an accreditation
program, and other related purposes.
Nonetheless, funding remains inadequate,
says Heinrich. 
However, all these oversight strategies
are looking at the problem from the wrong
perspective, says Wiles. He believes public
health is best protected by more stringent
pollutant exposure standards than now exist.
Those standards can be tightened based on
existing knowledge, he says, and additional
testing on humans only helps delay imple-
mentation of more protective standards.
The idea that human data help tighten pol-
lutant exposure standards is, he says, “sort of
naive. Polluters will always find a way to ask
for that next study.” 
If researchers do continue to use human
test subjects, government oversight needs to
keep improving, Heinrich said in her pub-
lished testimony: “Overall, HHS’s actions
appear promising, but we have some con-
cerns about the pace and scope of the
department’s efforts to ensure the safety and
protection of participants in clinical trials.”
And the onus isn’t solely on the govern-
ment. “There are basic rules,” she said while
discussing the June 2001 incident at Johns
Hopkins. “If investigators aren’t following
them, the whole system breaks down.”
Bob Weinhold
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A Laundry List of Concerns
Additional problems that permeate the system for protecting human test subjects, as
identified by oversight agencies and independent critics, include: 
• lack of a single, independent federal management organization, although sources
at the Office for Human Research Protections (OHRP) say that working within
the current framework may still be viable if other weaknesses in the system are
remedied;
• lack of a unified, comprehensive policy for all types of research involving human
test subjects, including studies done by private organizations;
• lack of education among both study participants and researchers about human test
subjects, although that is changing, with “an enormous amount of educational
activity going on,” OHRP sources say, including conference, courses, and intra-
agency efforts;
• professional, financial, and ethical conflicts among study sponsors, institutional
review boards (IRBs), data monitoring committees, researchers, and test subjects;
• lack of basic information on and accreditation of thousands of institutions and
IRBs doing and overseeing research, although a recommendation to have institu-
tions register their IRBs with the Department of Health and Human Services
(HHS) is being phased in, and a pilot method for accrediting organizations was
recommended in April 2001 by the Institute of Medicine;
• extensive problems in reviewing and reporting adverse events;
• lack of appropriate expertise and suitable points of view on some IRBs;
• lack of funding commitments for IRBs when organizations apply for study
approval;
• poor on-site auditing of studies, although the number of visits is up significantly,
and is scheduled by the OHRP to continue increasing; even with those increases,
however, only a tiny fraction of all research organizations will be audited on-site;
• poor coordination of international studies that may be conducted under varying
standards;
• lack of a requirement for complete provision of data by a sponsor before a study
begins;
• questionable statistical power in small studies;
• questionable applicability of human tests in understanding chronic health effects
(this difficulty may be hard to overcome, as few researchers want to deliberately
expose test subjects for any lengthy period);
• infrequent long-term tracking of test subjects to monitor subsequent health effects;
• uneven selection of participants, sometimes targeting those who are otherwise
unrepresentative of society and who don’t stand to gain proportionately from the
research; and 
• inadequate penalties for violations, although legislation that would permit civil
monetary penalties is under consideration by the HHS; however, the OHRP
frowns on fines, favoring oversight and, when necessary, disciplinary action and
litigation.